Tag Archives: Nuzyra

NUZYRA Continues to be the Primary Driver for Paratek Pharmaceuticals’ Growth

The FDA approved Paratek’s supplemental New Drug Application (sNDA) for the oral-only dosing regimen of NUZYRA® for the treatment of adults with Community-Acquired Bacterial Pneumonia (CABP)